VivoSeq
Rare Disease

Von Hippel-Lindau Disease

16

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Von Hippel-Lindau Disease is an emerging landscape with 16 programs across 7 companies. The most active players are Roche, Merck & Co., Bristol-Myers Squibb. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

6/100

Mech. Concentration

8/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 3Eisai logo

Eisai

1 program

Phase 3Novartis logo

Novartis

2 programs

Phase 3Pfizer logo

Pfizer

3 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

14 of 16 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody213%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Recruiting2 · 33%

Clinical Trials

Trial Activity

6 trials

Propranolol and Von Hippel-Lindau Disease
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT05424016·85 enrolled
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT07405164·450 enrolled
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT03108066·4 enrolled
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT02108002·7 enrolled
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Completed·National Cancer Institute (NCI)·Phase 2·NCT00088374·9 enrolled
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Completed·National Eye Institute (NEI)·Phase 1/2·NCT02859441·3 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)